OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit

🚨 We are #OncoAlert | Oncology360°

[OncoAlert @OncoAlert]

Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.

Register to receive it 👉 https://t.co/NhtuRoJ6DB

Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.

We are OncoAlert🚨 For Colleagues, by Colleagues

Best,
The Network

@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

A MASSIVE THANKS TO THE #ESMO26 PULSE

To our Amazing Senior Faculty🚨and our Awesome #OncoAlertAF You are all amazing and proud to be among you!!

We Come from different places but at the end
WE ARE ALL OncoAlert 🌐 Save travels to all flying today!!

[Tom Powles @tompowles1]

The MOIO randomised phase 3 non-inferiority trial (n=340) explored early discontinuation of ICI therapy be SOC in advanced patients responding to therapy. It had many flaws (mixed tumors and treatments, small size, early discontinuation etc). Also, due to the statistics, it’s not possible to say whether non-inferiority was achieved (OS HR 1.89 [95%Cl: 1.03,3.48]). Despite these problems it highlights a concern around early discontinuation, which should be taken seriously. Tumour specific trials are needed, but I’m not sure it will be easy to randomize patients . #ESMO26 @OncoAlert @myESMO @Annals_Oncology

[Yale Cancer Center @YaleCancer]

New study results from @Cecchini_OncMD show Telisotuzumab adizutecan + bevacizumab appeared to improve efficacy outcomes with a manageable safety profile in patients with advanced #colorectalcancer, and the regimen is currently being evaluated in a Phase III trial, AndroMETa-560. #ESMO26
https://t.co/7RxwFRxcE9
@SmilowCancer @myESMO @YaleGICancers @OncoAlert @Annals_Oncology

[Oncology Brothers @OncBrothers]

4. KEYNOTE-C93: PhIII, pembro mono vs carbo/paclitaxel in 1L dMMR advanced/recurrent endometrial ca

- mPFS 38.2 vs 8.4 mo (HR 0.57)
- G≥3 TRAEs 18.1% vs 50.7%
- DoR NR vs 10.2 mo
- OS immature. IO/ICI regardless of aite, in dMMR, this remains the preferred backbone.

5/5

[OncoAlert @OncoAlert]

🚨 FDA NEWS | By colleagues, for colleagues

Talazoparib + enzalutamide now approved for mAPMN/S prostate cancer with HRR gene mutations.TALAPRO-3 delivered a clear rPFS benefit (HR 0.48).
Full details & Key Facts graphic below.#OncoAlert #ProstateCancer #FDA

https://t.co/9GyssPz13e

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow**

📅 November 11–13, 2026
📍 New York, NY 🇺🇸
💻 Hybrid Meeting — In Person + Online

🎟️ FREE REGISTRATION with code: ONCOALERT
👉 https://t.co/8thlhgNeMR

For more than four decades, CFS® has brought together oncology professionals from around the world to explore the latest advances in cancer care.

This 3-day meeting will feature internationally renowned experts discussing practice-changing developments across **solid tumors and hematologic malignancies**, including:

🔹 Targeted therapies & immunotherapies\
🔹 Novel biomarkers and biomarker-driven treatment approaches\
🔹 Results from pivotal clinical trials\
🔹 Personalized treatment strategies based on evolving evidence\
🔹 Management of adverse events associated with novel therapies\
🔹 Emerging combination treatment strategies

🎓 Program Co-Chairs:
• Benjamin Levy, MD\
• John Mascarenhas, MD\
• Tiffany Traina, MD, FASCO

Don't miss this opportunity to connect with leaders in oncology, stay up to date on the latest evidence, and explore what’s next in cancer care.

🔗 **Register now:** https://t.co/8thlhgNeMR

@KCArbourMD @mishabeltran @KellyLBolton @HosseinBorghaei @AjaiChari @End\_myeloma @DrPinkalDesai @FordePatrick @MattGalsky @YJanjigianMD @DrHKantarjian @montypal @szusmani @HelenaYu923 @gotoPER

[Hidehito HORINOUCHI @HHorinouchi]

🆙#ESMO26 Poster: #LCSM
🔥Phase II Study of Izalontamab Brengitecan (Iza-Bren) Plus Osimertinib in Patients With EGFR Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
🎙️Dr. Fei Zhou
🔢2575P
🎯At 2.5mg/kg (n=40, 22.8-Mo Follow-Up): ORR 100%, cORR 97.5%, 18-Mo PFS 92.2%, mPFS/mDOR Not Reached
🎯Overall (n=154) ORR 86.4%; ILD 1.3%
☑️NCT05880706
🔗 https://t.co/7cTrjcAWZ5
@OncoAlert @Larvol @myESMO @IASLC

[Nicholas Hornstein @GIMedOnc]

Every company developing G12X drugs should pay attention to this data at #ESMO26

Zecdarasib (G12Di) plus chemo in 1L metastatic PDAC, phase 1

ORR 89% with mFOLFIRINOX (n=27)
ORR 69% with gem/nab-paclitaxel (n=26)

Awesome safety for early DE.

For context, other early 1L PDAC response rates (cross-trial which we would neeeeever do):

Zoldonrasib + FOLFIRINOX: 82%
Zoldonrasib + gem/nab-P: 61%
Daraxonrasib + gem/nab-P: 59%
Daraxonrasib alone: 47%

Chemo clearly still matters. Starting to think about this like Breakwater…

In PDAC, monoallelic inhibitors are extremely effective, just more effective with a little extra oomph behind them.

They will land in adjuvant, neoadjuvant, metastatic and every space you can imagine in the next few years.

Question is do we combo single plus pan or single plus chemo, and what is the added agent (especially in CRC)?

@OncoAlert @TheGutOncLab @Onco_Nexus @Incyte

[Hidehito HORINOUCHI @HHorinouchi]

🆙#ESMO26 Poster: #LCSM
🔥NADIM II: Post-Surgical Molecular Residual Disease and Pathological Complete Response After Perioperative Nivolumab in Resectable Stage III NSCLC: Exploratory Analysis
🎙️Dr. Pilar Mediavilla Medel
🔢2566P
🎯pCR Uniformly MRD-Negative With 5-Yr OS 95.7%, PFS 91.3%
🎯In Non-pCR, Detectable MRD Defined High-Risk Group (Median OS 22.3mo, PFS 10.4mo) vs Undetectable MRD (Not Reached)
☑️NCT03838159
🔗 https://t.co/6FnQtybdPM
@OncoAlert @Larvol @myESMO @IASLC

[Oriol Mirallas MD @DrMirallas]

#ESMO26
🚀 Presidential session #3

📌 MOIO is an academic, multicentre, phase III non-inferiority trial conducted across 36 French centres.
🗣️ Dr. Gravis

👫🏽 Pts with locally advanced/metastatic solid tumors in partial or complete response (CR) after 6 months of standard-dose IO were eligible (melanoma in CR excluded)

👉🏽 14 different tumor types
👉🏽 Multiple #ICI combinations
👉🏽👉🏽 Inconclusive study!
❓ Worse OS for NSLC and urothelial
❓ Better OS in HNSCC and RCC

⚠️Are we ok for a HR of 1.3 for non-inferiority threshold?

Great discussion by @DrJNaidoo

@OncoAlert @myESMO @ASCO @_SEOM @VHIO @brunolarvol
👇🏽👇🏽

[Nieves Martinez Lago MD PhD @DraMartinezLago]

#ESMO26 🧬 Presidential | 🇨🇳 ARTEMIS-011

👥 122 pts | R/R osteosarcoma
💊 Ris-Rez (B7-H3 ADC) vs gemcitabine/docetaxel

📈 mPFS: 5.5 vs 1.4 mo (HR 0.33)
🎯 ORR: 15% vs 2%
✅ DCR: 76% vs 33%
⏳ OS immature (HR 0.51)

⚠️ G≥3 TRAEs: 93% vs 83%

💡 Promising new strategy!

@OncoAlert

[OncoAlert @OncoAlert]

Dear #ESMO26 We Are ALL @OncoAlert 🚨
For Colleagues...By Colleagues

@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @Erman_Akkus @weoncologists

[OncoAlert @OncoAlert]

🎬 New OncoAlert #Podium2Screen 🎬 from #ESMO26

Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA

@elmayermd, @stolaney1, @GregoryAVidal, @jhaveri_komal, @breastoncdoc, @DrWGradishar, @NaokiNiikura, @FavretMD, @DraAlfie, @hoperugo

🔹 Giredestrant + everolimus kept its PFS benefit regardless of ctDNA fraction
🔹 Benefit held across ESR1 variants, including Y537 (HR 0.35)
🔹 Benefit also held in poor-prognosis subgroups (TP53, GATA3, RB1)

Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76

[OncoAlert @OncoAlert]

🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!

In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.

🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.

These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.

While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?

🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.

Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76

[OncoAlert @OncoAlert]

🚨 #ESMO26 #Podium2Screen: LITESPARK-012 in advanced #RCC

Our @OncoAlert founding faculty @DrChoueiri presents

➡️ Adding belzutifan or CTLA-4 blockade (quavonlimab) to pembrolizumab + lenvatinib did NOT improve PFS, OS or ORR (n=1688)
@tompowles1 @MVossMD @ERPlimackMD
@HowardGurney @brian_rini

➡️ Higher discontinuation rates in the triplet arms
Pembro + lenvatinib remains a 1L standard 👇

#KidneyCancer

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC

Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:

➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC

Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:

➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

OncoAlert founding faculty Dr. Toni Choueiri 🇺🇸 of Dana Farber walks us through adjuvant pembrolizumab vs placebo in high-risk ccRCC:

📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.

▶️ Watch now 👇
#kidneycancer #RCC #kidneycancer

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3

[OncoAlert @OncoAlert]

An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session

Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial

@jteoh_hk @CPRT65

🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).

Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj

Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.

➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)

➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance

➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control

➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control

✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.

🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto

@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3